TIDMINS
Instem plc
22 November 2021
Instem plc
("Instem" or the "Company")
New In Silico Software Release
Enhanced Informatics Software Boosting Client Offering and
Revenue Streams
Instem plc (AIM: INS), a leading provider of IT solutions to the
global life sciences market, announces the release of the latest
edition of its Leadscope Model Applier computational toxicology
software solution. This release includes a comprehensive package of
new and updated models to meet the growing market demand for in
silico solutions and is expected to create the following
opportunities for Instem:
-- New routes to market
-- Increased revenue streams
-- Strengthened in silico offering
-- Increased regulatory-backed solutions
The core software capabilities have been enhanced significantly,
enabling clients to deploy a unique, highly-differentiated solution
developed with considerable regulatory and industry collaboration.
The new software brings compelling benefits; reducing the time to
bring products to market, the risk of costly later stage R&D
failure and use of animal experimentation.
The software includes four new chargeable models. These include
a first-to-market Bioactivation Profiler, which was developed in
conjunction with regulators and industry. Additionally, the new
Abuse Liability Profiler is believed to be the first commercial in
silico tool in the market, further differentiating Instem from its
competitors and broadening routes to market.
Renowned for its advanced informatics and prediction technology,
together with comprehensive database solutions, Instem's in silico
solutions enable organizations around the world to effectively
unlock valuable knowledge contained in both public and proprietary
sources of research data. Clients can also access well over 500,000
toxicology studies for more than 200,000 chemicals, enabling fast,
accurate, defendable and regulatory-accepted predictions.
Dr. Glenn Myatt, VP Informatics of Instem plc, said: "The 2021
software release supports the continued global demand for reliable
alternatives to traditional testing methods. Industry and
regulators alike are increasingly recognizing the huge benefits of
computational toxicology approaches and we are seeing strong and
sustained growth in the acceptance and adoption of in silico
methods.
This latest software release enables existing and prospective
clients to accelerate their drug discovery and development
processes by ensuring fast, accurate, defendable and regulatory
accepted predictions for an increasing range of applications."
Phil Reason, CEO of Instem plc, said: "We are delighted to have
released this new 2021 software. This update further consolidates
Instem's position as the leading provider of alternative testing
methods, delivering powerful new in silico models and
first-to-market capabilities.
Since acquiring Leadscope in November 2019, we have seen
compound annual growth rates for their software subscriptions of
c.17% and pay-per-use growth of 21% per annum. These new predictive
models provide further opportunity for revenue expansion."
For further information, please contact:
Instem plc Via Walbrook
Phil Reason, CEO
Nigel Goldsmith, CFO
Singer Capital Markets (Nominated
Adviser & Broker) +44 (0) 20 7496 3000
Peter Steel
Alex Bond
Rachel Hayes
Walbrook Financial PR +44 (0) 20 7933 8780
Tom Cooper instem@walbrookpr.com
Nick Rome
Nicholas Johnson
About Instem
Instem is a leading provider of IT solutions & services to
the life sciences market delivering compelling solutions for Study
Management Regulatory Submissions, Clinical Trial Acceleration, and
Informatics-based Insight Generation.
Instem solutions are in use by over 700 customers worldwide,
including all the largest 25 pharmaceutical companies, enabling
clients to bring life enhancing products to market faster. Instem's
portfolio of software solutions increases client productivity by
automating study-related processes while offering the unique
ability to generate new knowledge through the extraction and
harmonisation of actionable scientific information.
Instem products and services address aspects of the entire drug
development value chain, from discovery through to market launch.
Management estimate that over 50% of all drugs on the market have
been through some part of Instem's platform at some stage of their
development.
To learn more about Instem solutions and its mission, please visit www.instem.com
About Leadscope
Founded in 1997, Leadscope is based in Columbus, Ohio, USA and
is a leading provider of in silico safety assessment software used
to enhance and accelerate life sciences research and development.
Developed, in part, through several Research Collaboration
Agreements ("RCAs") with the US Food & Drug Administration
("FDA"), its solutions use a database of over 500,000 toxicity
studies for over 200,000 chemicals covering all major potential
safety-related risks.
Provided on a subscription or pay-per-use basis, Leadscope's
software employs sophisticated artificial intelligence and
machine-learning algorithms to predict potential safety outcomes
and to enable scientists to perform expert reviews. Deployed as
Software-as-a-Service, or on client premises, Leadscope's software
allows clients to extract knowledge from both public data and their
own proprietary sources. Commencing in early 2021, access to the
Leadscope technology was additionally made available through a new
Predict(TM) service.
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
Reach is a non-regulatory news service. By using this service an
issuer is confirming that the information contained within this
announcement is of a non-regulatory nature. Reach announcements are
identified with an orange label and the word "Reach" in the source
column of the News Explorer pages of London Stock Exchange's
website so that they are distinguished from the RNS UK regulatory
service. Other vendors subscribing for Reach press releases may use
a different method to distinguish Reach announcements from UK
regulatory news.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRABLBATMTJBBFB
(END) Dow Jones Newswires
November 22, 2021 02:00 ET (07:00 GMT)
Instem (LSE:INS)
Historical Stock Chart
From Jun 2024 to Jul 2024
Instem (LSE:INS)
Historical Stock Chart
From Jul 2023 to Jul 2024